Boston Scientific (Natick Massachusetts) reported a second-quarter profit that beat expectations and forecast growth in the third period on improved sales of its surgical devices and cardiology products. The company generated sales of $1.809 billion and adjusted EPS of 18 cents. Shares rose 9.1% to $10.49 in early trading.